AptarGroup, Inc. (ATR) – Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for AptarGroup, Inc. for the period ended June 30, 2025. AptarGroup is a global manufacturer of dispensing, dosing, and protection technologies for the pharmaceutical, beauty, and food/beverage markets. The company operates through three segments: Aptar Pharma, Aptar Beauty, and Aptar Closures.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $966.0 million | $910.1 million | $1,853.3 million | $1,825.5 million |
| Operating Income | $144.4 million | $126.0 million | $257.8 million | $238.1 million |
| Net Income (Attributable to Aptar) | $111.7 million | $90.5 million | $190.5 million | $173.6 million |
| Diluted EPS | $1.67 | $1.34 | $2.83 | $2.57 |
| Adjusted EBITDA | $218.4 million | $192.8 million | $401.7 million | $371.6 million |
| Free Cash Flow (YTD) | $91.7 million (2025) vs $92.0 million (2024) | |||
| Cash & Equivalents | $161.7 million | (Balance Sheet: Dec 31, 2024: $223.8 million) | ||
| Total Debt | $1,086.6 million | (Balance Sheet: Dec 31, 2024: $1,026.4 million) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 net sales increased 6% year-over-year, driven by a 3% core sales increase and a 3% positive currency translation impact. All three segments contributed to core growth.
- Profitability: Operating margin improved to 15.0% in Q2 2025 from 13.8% in Q2 2024. Adjusted EBITDA margin expanded to 22.6% from 21.2%.
- Segment Performance:
- Aptar Pharma: Sales up 7% (3% core growth) driven by prescription drug and injectables demand. Adjusted EBITDA margin improved to 35.4%.
- Aptar Beauty: Sales up 4% (1% core growth). Core sales were impacted by softer demand in prestige fragrance and indie skincare, offset by personal care growth.
- Aptar Closures: Sales up 8% (7% core growth) led by strong food and beverage market performance.
- Tax Rate: The effective tax rate for Q2 2025 was 20.0%, lower than the 23.5% in Q2 2024, primarily due to an $8.3 million deferred tax benefit from the release of a valuation allowance.
- Debt & Liquidity: Total debt increased to $1.09 billion from $1.03 billion at year-end 2024. Net Debt to Net Capital ratio increased slightly to 25.2%.
Guidance, Outlook, and Risks
- Q3 2025 Guidance: Management expects diluted earnings per share in the range of $1.53 to $1.61, excluding restructuring, investment fair value changes, and acquisition costs. This assumes an effective tax rate of 20.5% to 22.5%.
- Capital Expenditures: Total 2025 estimated cash outlays for capex are expected to be $270 million to $290 million (net of government grants).
- Share Repurchases: The company repurchased $150.0 million of stock in the first six months of 2025. Approximately $312.7 million remains available under the current $500 million authorization.
- Dividends: A quarterly dividend of $0.45 per share was declared, payable August 14, 2025.
- Key Risks:
- Geopolitical conflicts and supply chain disruptions.
- Fluctuations in foreign currency exchange rates (primary exposure to Euro).
- Impact of tariffs and trade restrictions.
- Raw material costs and availability.
- Integration of recent acquisitions (e.g., BTY).
Investor Verification Checklist
- Valuation Allowance Release: Verify the sustainability of the $8.3 million tax benefit from the valuation allowance release and its impact on future effective tax rates.
- BTY Acquisition: Monitor the closing and accounting of the additional 31% stake in BTY (closed July 28, 2025), which is expected to generate a ~$23 million non-cash gain in Q3 2025.
- Core Sales Momentum: Assess whether the 3% core sales growth in Q2 can be sustained given the softer demand noted in the Beauty segment's prestige fragrance and indie skincare categories.
- Debt Covenants: Confirm continued compliance with the Consolidated Leverage Ratio (currently 1.19x vs. 3.50x max) and Interest Coverage Ratio (currently 17.40x vs. 3.00x min).
- Free Cash Flow: Review the trend in free cash flow generation against the increased capital expenditure requirements for growth projects.